MarketCatalyst
← Back to Resources
Earnings

Generate Biomedicines Misses Q3 2026 Estimates

Revenue of $4.2M vs. $7.8M expected and adjusted EPS of -$0.68 vs. -$0.56.

Published Nov 12, 2026 · 7:17 AM ET · 2 min read

Generate Biomedicines (GENB) missed estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $4.2 million below the $7.8 million estimate, and adjusted EPS was -$0.68 below the -$0.56 estimate.

Shares fell 4.7% in premarket trading as of 7:08 a.m. ET, to $12.85 from a $13.49 close.

-$0.68
Adjusted EPS vs. -$0.56 estimate
$4.2M
Revenue vs. $7.8M estimate
-4.7%
Shares premarket as of 7:08 a.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$0.56-$0.68Miss by 22%
Revenue$7.8M$4.2MMiss by 46%
ChangeQoQ
Adjusted EPS▼ 31%
Revenue▼ 33%

By our calculation, revenue was $3.5 million below the estimate and adjusted EPS was $0.12 below it. The QoQ column compares with the previous quarter's revenue of $6.3 million and adjusted EPS of -$0.52.

Track record

  • EPS record. Adjusted EPS beat the estimate in 0 of the last 2 reports, including this one.
  • Revenue record. Revenue beat the estimate in 1 of the last 2 reports.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$0.58 and revenue of $7.7 million next quarter, based on 3 analysts.
  • Estimate record. Whether Generate Biomedicines returns to beating EPS estimates, which it did in 0 of its last 2 reports.
  • Share reaction. How shares trade in the next regular session after the 4.7% decline in premarket trading.
  • Related coverage. See our reports on Cellebrite DI, DPC, NIQ Global Intelligence and SOLV Energy.

Sources: Results are from Generate Biomedicines's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Generate Biomedicines's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.

Generate Biomedicines Misses Q3 2026 Estimates